Unique ID issued by UMIN | UMIN000014264 |
---|---|
Receipt number | R000016617 |
Scientific Title | Prospective cohort study on liver disease-related tumor markers (DCP, NX-DCP, and NX-DCP-R) in patients with hepatitis C, cirrhosis, and hepatocellular carcinoma-influence by severe alcoholics |
Date of disclosure of the study information | 2014/06/15 |
Last modified on | 2014/06/15 03:05:17 |
Prospective cohort study on liver disease-related tumor markers (DCP, NX-DCP, and NX-DCP-R) in patients with hepatitis C, cirrhosis, and hepatocellular carcinoma-influence by severe alcoholics
Prospective cohort study on liver disease-related tumor markers in patients with hepatitis C, cirrhosis, and hepatocellular carcinoma-influence by severe alcoholics
Prospective cohort study on liver disease-related tumor markers (DCP, NX-DCP, and NX-DCP-R) in patients with hepatitis C, cirrhosis, and hepatocellular carcinoma-influence by severe alcoholics
Prospective cohort study on liver disease-related tumor markers in patients with hepatitis C, cirrhosis, and hepatocellular carcinoma-influence by severe alcoholics
Japan |
Hepatitis C, cirrhosis, and hepatocellular carcinoma
Hepato-biliary-pancreatic medicine |
Malignancy
NO
We aim to evaluate liver fibrosis by NX-DCP in hepatitis C and cirrhotic patients. In addition, we aim to investigate specificity of NX-DCP-R in severe alcoholic patients with hepatitis C, cirrhosis, and hepatocellular carcinoma.
Bio-availability
Confirmatory
The evaluation of liver fibrosis by NX-DCP in hepatitis C and cirrhotic patients
The evaluation of specificity of NX-DCP-R in severe alcoholic patients with hepatitis C, cirrhosis, and hepatocellular carcinoma
Observational
18 | years-old | <= |
Not applicable |
Male and Female
The determination of chronic hepatitis C was made using standard diagnostic criteria: serological detection of HCV antibodies and positive serum HCV-RNA by polymerase chain reaction for at least 6 months. All patients were naïve to antiviral treatment.
We excluded patients who were taking warfarin, antibiotics, or vitamin K supplementation before laboratory measurements.
700
1st name | |
Middle name | |
Last name | Masaya Saito |
Kobe University Hospital
Gastroenterology
7-5-2 Kusunoki-cho, Chuo-ku, Kobe
078-382-5111
masaya@med.kobe-u.ac.jp
1st name | |
Middle name | |
Last name | Masaya Saito |
Kobe University Hospital
Gastroenterology
7-5-1 Kusunoki-cho, Chuo-ku, Kobe
078-382-6305
masaya@med.kobe-u.ac.jp
Kobe University Hospital
none
Self funding
NO
2014 | Year | 06 | Month | 15 | Day |
Unpublished
Enrolling by invitation
2013 | Year | 06 | Month | 20 | Day |
2013 | Year | 06 | Month | 20 | Day |
2015 | Year | 03 | Month | 31 | Day |
we investigate serum NX-DCP and NX-DCP-R.
2014 | Year | 06 | Month | 15 | Day |
2014 | Year | 06 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016617
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |